INTRODUCTIONAspirin and clopidogrel significantly reduce the risk of myocardial infarction (MI), stroke, vascular events or cardiovascular death compared with placebo. According to the current American College of Cardiology (ACC)/American Heart Association (AHA) guidelines, dual antiplatelet therapy (DAPT) is recommended after percutaneous coronary and peripheral vascular interventions, MI and ischemic stroke.However, these benefits are offset to some degree by an increased risk of bleeding, especially gastrointestinal (GI) bleeding. Several large randomized cardiovascular trials have confirmed the association of DAPT with an increased risk of GI bleeding compared with aspirin therapy alone. In patients undergoing percutaneous coronary intervention, GI bleeding is a common cause of non‐access site bleeding and has been associated with increased inpatient morbidity and mortality.However, while a plethora of large‐scale studies show the incidence, predictors and prognosis of DAPT‐related GI bleeding, there is a relative paucity of evidence on the etiology of such bleeding. This is mostly because these large randomized studies were performed to assess the effect of DAPT on cardiovascular outcomes, and GI bleeding was only one out of a large number of events that were recorded. These studies did not report on the etiology of GI bleeding, just on their incidences and severity. The available
Journal of Digestive Diseases – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera